March Quarterly Appendix 4C

March Quarterly Appendix 4C

Cardiex Limited (CDX:AU) has announced March Quarterly Appendix 4C

Download the PDF here.

The Conversation (0)
FY25 Preliminary Results Summary and Company Update

FY25 Preliminary Results Summary and Company Update

Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
Appendix 4E

Appendix 4E

Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
June Quarterly Appendix 4C

June Quarterly Appendix 4C

Cardiex Limited (CDX:AU) has announced June Quarterly Appendix 4CDownload the PDF here. Keep Reading...
June Quarterly Activities Report

June Quarterly Activities Report

Cardiex Limited (CDX:AU) has announced June Quarterly Activities ReportDownload the PDF here. Keep Reading...
Results of Entitlement Offer

Results of Entitlement Offer

Cardiex Limited (CDX:AU) has announced Results of Entitlement OfferDownload the PDF here. Keep Reading...
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the... Keep Reading...
Lexaria Bioscience Corp. (Nasdaq: LEXX)

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization (“CRO”) to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of... Keep Reading...
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Contracts signed for Animal Study GLP-1-A26-1 KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO")... Keep Reading...
Microscope and syringe overlay a digital stock chart with green lines and numbers.

Kailera, Alamar Target Billion-Dollar Valuations in Biotech Revival

Biotechnology initial public offerings (IPOs) are regaining momentum as easing market headwinds and an appetite for weight-loss drugs coax companies back to the public markets.On Monday (April 13) Reuters reported, that obesity drug developer Kailera Therapeutics and proteomics firm Alamar... Keep Reading...
Transparent blue cells with dark centers floating against a vibrant blue background.

Biotech and Pharma Market Update: Q1 2026 in Review

After a strong performance toward the end of 2025, the life science sector began the new year on a constructive note. Looking forward, signals in Q1 point to a market continuing to reward proof over promise. In an interview with the Investing News Network (INN), Eric Shrayer, partner and... Keep Reading...
A glass flask on a reflective table with overlaid stock market charts and numerical data, including text reading: 0.00%.

Anthropic Inks US$400 Million Deal for AI Biotech Startup Coefficient Bio

AI developer Anthropic is acquiring New York-based biotech startup Coefficient Bio for approximately US$400 million, according to The Information.Founded just last fall and operating largely in stealth, Coefficient Bio will be absorbed directly into Anthropic’s healthcare life sciences... Keep Reading...

Interactive Chart

Latest Press Releases

Related News